“Generic Manufacturer Representation Cannot Provide The Necessary Evidence Of Specific Intent To Induce Infringement. Alleging Infringement.”
The U.S. Attorney General on Wednesday filed a brief hearing with the U.S. Supreme Court to grant Teva Pharmaceuticals’ motion for a ruling related to generic manufacturers’ liability for infringement through the use of “skinny labels” on generic drugs.
SG’s brief says that the US Court of Appeals for the Federal Circuit (CAFC) made a mistake, and the decision was designed to encourage new brand-name drugs and to allow cheaper generic drugs to enter the market. It could upset the careful balance contemplated by the Hatch-Waxman Amendment between making .
Under section viii of the Hatch-Waxman Amendment to the Federal Food, Drug, and Cosmetic Act, generic drug manufacturers may submit to the Food and Drug Administration (FDA) labels for generic drugs that are “cut off” from the brand’s approved label. increase. It’s still a patented use. Teva filed a section viii statement for a generic carvedilol drug in 2007, omitting the labeling portion of Coreg, a branded version of the drug for GlaxoSmithKline (GSK) that corresponds to the claimed use in U.S. Patent No. 5,760,069. Did. Therefore, information such as indications for first use of Coreg’s label for “Treatment of Mild to Severe Heart Failure” and dosing instructions for omitted use was not included in Teva’s label.However, GSK sued Teva in 2011 in Delaware District Court, claiming that Teva’s marketing
The distribution efforts also prompted physicians to prescribe generic carvedilol to treat congestive heart failure, infringing the uses claimed in GSK’s reissued patent granted in 2008. rice field.
The Court of Appeals for the Federal Circuit has twice decided to vacate post-judgment judgments by district courts that ruled Teva as a matter of law. In overturning those rulings, the Federal Circuit agreed with his GSK that Teva induced infringement of the reissue patent based on substantial evidence of his induced activity of Teva in support of the jury verdict. bottom. Both rulings featured his 30-page dissenting opinion from Circuit Judge Sharon Prost, who was the Federal Circuit’s Chief Justice when the first reversed judgment was issued in October 2020. Hatch-Waxman Act.
“Uncertainty about the section viii pathway is likely to discourage generic manufacturers from invoking the mechanism, thereby potentially threatening the availability of low-cost generic drugs, contrary to statutory design.” There is,” SG wrote in its Amicus brief.
The question posed by Teva asks the court: Are you intentionally facilitating the infringement of those decoupled uses?”
However, GSK stated in its response summary that the question was “blatantly misleading” and presented a question of its own. Can I be held liable for induced patent infringement simply because one of the two indications corresponding to the patent use was not included on the label (i.e., “engraved”)?
GSK claims the case involves “a situation that is highly unlikely to be repeated”, but SG should give the court a ruling to ensure the continued functioning of the system. “If the FDA and the generic manufacturer cannot rely on the NDA holder’s agent to explain what part of the original drug’s labeling indicates the patented use, the section viii pathway will will not function properly,” the government wrote. In the case of the Teva label in question, SG said the CAFC’s decision was “wrong” and that upholding the decision would have far-reaching implications for the ability of generic manufacturers to enter the market.
“A generic manufacturer’s representation cannot provide the requisite evidence of specific intent to induce infringement. Alleging infringement.”
SG further stated that the non-distinct language on Teva’s label describing the patented process could be considered evidence that Teva’s intent to encourage its use was “inappropriate here.” claimed it could. SG explained:
“The severed labeling did not reflect petitioner’s unencumbered choice, but was instead driven by FDA regulatory requirements and GSK’s own identification of indications to be removed…. Whatever inferences may be drawn from the manufacturer’s unilateral labeling choices that are found to encourage use,[t]His law simply does not permit negligent and willful inferences of encouragement. [petitioner’s] Label for this record.
GSK also argued that the case was factual and unusual, noting that “induction liability can arise in such circumstances, and even if such liability is seldom Even if not imposed, it could significantly discourage the use of section viii pathways,” SG added.
In support of Teva, so far four other Amichi have been complicit in the case.
